Amendments to the Claims

1. (Original) A compound having a structural Formula I,

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

E is: $O, S \text{ or } NR^{14};$

W is:

$$\begin{tabular}{ll} $X = X^4 - X^5 \\ $R^4 - R^5$ \ , hydrogen, C_1-$C_6 alkyl, $(CH_2)_n$-C_3-$C_6 cycloalkyl, haloalkyl or acyl; $(CH_2)_n$-$C_6 cycloalkyl, $(CH_2)_n$-$C_6 cycloalkyl,$$

Q is: $-C(O)OR^6$ or R^{6A} ;

X is: a bond, C, O, S or S[O]_p;

Y is: a bond, S, C or O;

Z is: a) aliphatic group,

- b) aryl,
- c) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
- d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,

e) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and

f) heterocyclyl;

wherein aliphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl being optionally substituted with one or more groups independently selected from R¹⁵;

```
m and n' are each independently: 0, 1, 2, 3 or 4;
          0, 1, 2 or 3;
n is:
p is:
          1 or 2;
r is:
          1, 2, 3 or 4;
v is:
          1 or 2;
R<sup>1</sup> is: hydrogen, wherein when Z is phenyl or naphthyl and R<sup>2</sup> is H, R<sup>1</sup> is not H,
          haloalkyl,
          C<sub>1</sub>-C<sub>6</sub> alkyl,
          C_1-C_6 alkyl-C_1-C_6 alkoxy,
          C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,
          C<sub>2</sub>-C<sub>6</sub> alkenyl,
          C<sub>2</sub>-C<sub>6</sub> alkynyl,
          (CH<sub>2</sub>)<sub>n</sub>,C<sub>3</sub>-C<sub>6</sub> cycloalkyl,
          C_1-C_6 alkoxy,
          aryl, or
          R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and
          wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted
          with one or more groups independently selected from R<sup>15</sup>;
```

R^{1a} and R^{1b} are each independently:

hydrogen,

C₁-C₆ alkyl, or

R¹ and R^{1a}, R¹ and R^{1b}, R² and R^{1a}, R² and R^{1b} or R^{1a} and R^{1b} together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of R^{1a} and R^{1b} is not hydrogen;

```
R<sup>2</sup> is: hydrogen,
          haloalkyl,
          C_1-C_6 alkyl,
          C_1-C_6 alkyl-C_1-C_6 alkoxy,
          C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,
          C<sub>2</sub>-C<sub>6</sub> alkenyl,
          C<sub>2</sub>-C<sub>6</sub> alkynyl,
          (CH<sub>2</sub>)<sub>n</sub>,C<sub>3</sub>-C<sub>6</sub> cycloalkyl,
          C_1-C_6 alkoxy,
          aryl, or
          R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and
          wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted
          with one or more groups independently selected from R<sup>15</sup>;
R<sup>2a</sup> is: hydrogen, halo or C<sub>1</sub>-C<sub>6</sub> alkyl and wherein R<sup>2</sup> and R<sup>2a</sup> together being a 3- to 8-membered
          ring; and wherein alkyl being optionally substituted with one or more groups
          independently selected from R<sup>15</sup>;
R<sup>3</sup> is: hydrogen,
          halo,
          cyano,
          haloalkyl,
          C_1–C_6 alkyl,
          (CH<sub>2</sub>)<sub>n</sub>·C<sub>3</sub>-C<sub>6</sub> cycloalkyl,
          (C<sub>1</sub>-C<sub>4</sub> alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted with
                    oxo,
          (C_1-C_4 \text{ alkyl})-NR^7C(O)_pR^9, and
          wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more
          groups independently selected from R<sup>15</sup>;
R<sup>4</sup> and R<sup>5</sup> are each independently:
          hydrogen,
          halo,
```

 C_1 - C_6 alkyl

 C_1 - C_6 alkoxy;

aryloxy;

 $N(R^8)_2$,

SR⁸ or

R⁴ and R⁵ together being a 3- to 8-membered ring;

R⁶ is: hydrogen, C₁-C₆ alkyl or aminoalkyl;

R^{6A} is: carboxamide, C₁-C₃ alkylnitrile, sulfonamide, acylsulfonamide or tetrazole;

R⁷ is: hydrogen or C₁-C₆ alkyl;

R⁸ and R⁹ are each independently:

hydrogen, C₁-C₆ alkyl, aryl, heteroaryl, or heterocyclyl, and wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C₁-C₆ alkyl and C₁-C₆ alkoxy;

 R^{14} is: hydrogen, aryl, C_1 - C_6 alkyl, or C_1 - C_6 alkyl-COOR⁶, and wherein aryl and alkyl being optionally substituted with one or more groups independently selected from R^{15} ; and

 $R^{15} \text{ is: } \text{hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy, $(CH_2)_n$.C_3-C_6 cycloalkyl, $N(R^8)_2$, $NR^8S(O)_2R^9$, $NR^8C(O)_pR^9$, $C(O)NR^8R^9$, $C(O)_pR^8$, SR^8, $S(O)_pR^8$ or $S(O)_2NR^8R^9$.}$

- 2. (Original) The compound Claim 1, wherein X and Y are respectively S and O; S and C; or C and O.
- $\label{eq:compound} 3. \qquad \text{(Original) The compound of Claim 2, wherein Z is C_1-$C_6 alkyl, aryl or heteroaryl.}$

4. (Original) The compound of Claim 3, wherein Z is phenyl, naphthyl, thiophenyl, oxazolyl, isooxazolyl, pyridyl, benzothiophenyl, benzofuranyl, indolyl, isoindolyl, pyrazolyl, imidazolyl, 1,4 benzodioxan, benzooxazolyl, benzothiazolyl, benzoimidazolyl, or 2,3-dihydrobenzofuranyl.

- 5. (Original) The compound of Claim 4, wherein R^1 is C_3 - C_6 alkyl or $(CH_2)_n$ - C_3 - C_6 cycloalkyl; R^2 and R^3 are each independently C_1 - C_3 alkyl; and r is 1.
- 6. (Original) The compound Claim 5, wherein X is positioned para to Y; and R^3 is positioned ortho to Y.
 - 7. (Original) A compound having a structural Formula II,

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

Q is: $-C(O)OR^6$ or R^{6A} ;

X is: a bond, C, O, S or $S[O]_p$;

Y is: a bond, S, C or O;

- Z is: a) aliphatic group,
 - b) aryl,
 - c) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
 - d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,

e) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and

f) heterocyclyl;

wherein aliphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl being optionally substituted with one or more groups independently selected from R¹⁵;

```
m and n' are each independently: 0, 1, 2, 3 or 4;
          0, 1, 2 or 3;
n is:
          1 or 2;
p is:
r is:
          1, 2, 3 or 4;
R<sup>1</sup> is: aryl,
          haloalkyl,
          C_1-C_6 alkyl,
          C_1-C_6 alkyl-C_1-C_6 alkoxy,
          C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,
          C<sub>2</sub>-C<sub>6</sub> alkenyl,
          C<sub>2</sub>-C<sub>6</sub> alkynyl,
          (CH<sub>2</sub>)<sub>n</sub>,C<sub>3</sub>-C<sub>6</sub> cycloalkyl,
          C<sub>1</sub>-C<sub>6</sub> alkoxy or
          R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and
          wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted
          with one or more groups independently selected from R<sup>15</sup>;
```

 R^{1a} and R^{1b} are each independently:

hydrogen,

C₁-C₆ alkyl, or

R¹ and R^{1a}, R¹ and R^{1b}, R² and R^{1a}, R² and R^{1b} or R^{1a} and R^{1b} together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of R^{1a} and R^{1b} is not hydrogen;

R² is: hydrogen, haloalkyl,

```
C<sub>1</sub>-C<sub>6</sub> alkyl,
          C_1-C_6 alkyl-C_1-C_6 alkoxy,
          C<sub>1</sub>-C<sub>6</sub> alkyl-aryl,
          C<sub>2</sub>-C<sub>6</sub> alkenyl,
          C<sub>2</sub>-C<sub>6</sub> alkynyl,
          (CH<sub>2</sub>)<sub>n</sub>,C<sub>3</sub>-C<sub>6</sub> cycloalkyl,
          C_1-C_6 alkoxy,
          aryl, or
          R<sup>1</sup> and R<sup>2</sup> together being a 5- to 8-membered heterocyclyl ring, and
          wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted
          with one or more groups independently selected from R<sup>15</sup>;
R<sup>2a</sup> is: hydrogen, halo or C<sub>1</sub>-C<sub>6</sub> alkyl and wherein R<sup>2</sup> and R<sup>2a</sup> together being a 3- to 8-membered
          ring; and wherein alkyl being optionally substituted with one or more groups
          independently selected from R<sup>15</sup>;
R<sup>3</sup> is: hydrogen,
          halo,
          cyano,
          haloalkyl,
          C_1-C_6 alkyl,
          (CH<sub>2</sub>)<sub>n</sub>,C<sub>3</sub>-C<sub>6</sub> cycloalkyl,
           (C<sub>1</sub>-C<sub>4</sub> alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted with
                     oxo,
          (C_1-C_4 \text{ alkyl})-NR^7C(O)_pR^9, and
          wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more
          groups independently selected from R<sup>15</sup>;
R<sup>4</sup> and R<sup>5</sup> are each independently:
          hydrogen,
          halo,
          C<sub>1</sub>-C<sub>6</sub> alkyl
```

 C_1 - C_6 alkoxy;

aryloxy;

 $N(R^8)_{2}$

SR⁸ or

R⁴ and R⁵ together being a 3- to 8-membered ring;

R⁶ is: hydrogen, C₁-C₆ alkyl or aminoalkyl;

R^{6A} is: carboxamide, C₁-C₃ alkylnitrile, sulfonamide, acylsulfonamide or tetrazole;

R⁷ is: hydrogen or C₁-C₆ alkyl;

R⁸ and R⁹ are each independently:

hydrogen, C₁-C₆ alkyl, aryl, heteroaryl, or heterocyclyl, and wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C₁-C₆ alkyl and C₁-C₆ alkoxy;

- R^{15} is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, $(CH_2)_n$, C_3 - C_6 cycloalkyl, $N(R^8)_2$, $NR^8S(O)_2R^9$, $NR^8C(O)_pR^9$, $C(O)_NR^8R^9$, $C(O)_pR^8$, SR^8 , $S(O)_pR^8$ or $S(O)_2NR^8R^9$.
- 8. (Original) The compound of Claim 7, wherein X and Y are respectively S and O; S and C; or C and O.
- 9. (Original) The compound of Claim 8, wherein Z is C_1 - C_6 alkyl, aryl or heteroaryl.
- 10. (Original) The compound of Claim 9, wherein Z is phenyl, naphthyl, thiophenyl, oxazolyl, isooxazolyl, pyridyl, benzothiophenyl, benzofuranyl, indolyl, isoindolyl, pyrazolyl, imidazolyl, 1,4 benzodioxan, benzooxazolyl, benzothiazolyl, benzoimidazolyl, or 2,3-dihydrobenzofuranyl.
- 11. (Original) The compound of Claim 10, wherein R^1 is C_3 - C_6 alkyl or $(CH_2)_n$ - C_3 - C_6 cycloalkyl; R^2 and R^3 are each independently C_1 - C_3 alkyl; and r is 1.

12. (Original) The compound Claim 11, wherein X is positioned para to Y; and R^3 is positioned ortho to Y.

13. (Original) The compound of Claim 7, wherein the compound having a structural Formula III,

$$Z \stackrel{\text{O}}{=} \begin{matrix} R^{1a} \\ \vdots \\ R^{4} \\ R^{1b} \end{matrix} \stackrel{\text{O}}{=} \begin{matrix} X \\ \vdots \\ R^{3} \end{matrix}_{r} \qquad \begin{matrix} X \\ R^{4} \\ R^{5} \end{matrix}$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

n is: 1 or 2;

r is: 1, 2, 3, or 4;

X is: S or C;

Y is: C or O;

Z is: aryl or a 5- to 10-membered heteroaryl,

wherein aryl and heteroaryl being optionally substituted with one or more groups independently selected from R¹⁵;

 R^1 and R^2 are each independently: C_1 - C_6 alkyl or $(CH_2)_{n'}C_3$ - C_6 cycloalkyl; and R^{1a} and R^{1b} , R^3 , R^4 and R^5 are each independently: hydrogen or C_1 - C_6 alkyl.

14. (Original) The compound of Claim 13, wherein the compound having a structural Formula IV,

$$(R^{12})_{q}$$

$$O$$

$$R^{1a}$$

$$S$$

$$R^{3}$$

$$R^{4}$$

$$R^{5}$$

$$IV$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof,

wherein:

q is 1, 2, 3, 4, or 5;

R⁸ and R⁹ are each independently:

hydrogen, C₁-C₆ alkyl, aryl, heteroaryl, or heterocyclyl,

wherein alkyl, aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C₁-C₆ alkyl and C₁-C₆ alkoxy; and;

$$\begin{split} R^{12} \text{ is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryl, heteroaryl, aryloxy,} \\ \text{oxo, } C_1\text{-}C_6 \text{ alkyl, } C_1\text{-}C_6 \text{ alkoxy, } (CH_2)_{n'}C_3\text{-}C_6 \text{ cycloalkyl, } N(R^8)_2, NR^8S(O)_2R^9, \\ \text{NR}^8C(O)_pR^9, C(O)NR^8R^9, C(O)_pR^8, SR^8, S(O)_pR^8 \text{ or } S(O)_2NR^8R^9. \end{split}$$

15. (Original) The compound of Claim 14, wherein the compound having a structural Formula V,

$$(R^{12})_1 \xrightarrow{\qquad \qquad \qquad \qquad \qquad } C$$

$$(R^{12})_2 \xrightarrow{\qquad \qquad \qquad } C$$

$$CO_2H$$

$$V$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein R^1 and R^2 are each independently C_1 - C_4 alky or $(CH_2)_n$ · C_3 - C_6 cycloalkyl; R^3 is C_1 - C_4 alky; $(R^{12})_1$ is halo, haloalkyl, or haloalkyloxy; and $(R^{12})_2$ is F, Cl or Br.

16. (Cancelled)

17. (Original) A compound having a structural Formula VI,

-13-

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

X is: a bond, C, O, S or S[O]_p;

Y is: a bond, S, C or O;

Z is: heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S, and wherein heteroaryl being optionally substituted with one or more groups selected from R¹⁵;

n is: 0, 1, 2 or 3;

n' is: 0, 1, 2, 3 or 4;

p is: 1 or 2;

r is: 1, 2, 3 or 4;

R¹ is: hydrogen,

haloalkyl,

 C_1 - C_6 alkyl,

 C_1 - C_6 alkyl- C_1 - C_6 alkoxy,

C₁-C₆ alkyl-aryl,

C₂-C₆ alkenyl,

C₂-C₆ alkynyl,

(CH₂)_n,C₃-C₆ cycloalkyl,

 C_1 - C_6 alkoxy,

aryl, or

R¹ and R² together being a 5- to 8-membered heterocyclyl ring, and wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R¹⁵;

R^{1a} and R^{1b} are each independently:

hydrogen,

C₁-C₆ alkyl, or

 R^1 and R^{1a} , R^1 and R^{1b} , R^2 and R^{1a} , R^2 and R^{1b} or R^{1a} and R^{1b} together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of R^{1a} and R^{1b} is not hydrogen;

R² is: hydrogen, haloalkyl, C₁-C₆ alkyl,

 C_1 - C_6 alkyl- C_1 - C_6 alkoxy,

C₁-C₆ alkyl-aryl,

C₂-C₆ alkenyl,

C₂-C₆ alkynyl,

(CH₂)_n·C₃-C₆ cycloalkyl,

 C_1 - C_6 alkoxy,

aryl, or

R¹ and R² together being a 5- to 8-membered heterocyclyl ring, and wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R¹⁵;

R^{2a} is: hydrogen, halo or C₁-C₆ alkyl and wherein R² and R^{2a} together being a 3- to 8-membered ring; and wherein alkyl being optionally substituted with one or more groups independently selected from R¹⁵;

R³ is: hydrogen,

halo,

cyano,

haloalkyl,

 C_1 – C_6 alkyl,

(CH₂)_n·C₃-C₆ cycloalkyl,

 $(C_1-C_4 \text{ alkyl})$ -heterocyclyl, wherein the heterocyclyl being optionally substituted with oxo, $(C_1-C_4 \text{ alkyl})$ -NR 7 C(O)_pR 9 , and

wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from R¹⁵:

R⁶ is: hydrogen, C₁-C₆ alkyl or aminoalkyl;

R⁷ is: hydrogen or C₁-C₆ alkyl;

R⁸ and R⁹ are each independently:

hydrogen, C_1 - C_6 alkyl, aryl, heteroaryl, or heterocyclyl, and wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1 - C_6 alkyl and C_1 - C_6 alkoxy; and

 $R^{15} \text{ is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy, $N(R^8)_2$, $NR^8S(O)_2R^9$, $NR^8C(O)_pR^9$, $C(O)NR^8R^9$, $C(O)_pR^8$, SR^8, $S(O)_pR^8$ or $S(O)_2NR^8R^9$.}$

18. (Original) The compound of Claim17, wherein the compound having a structural Formula VII,

$$(R^{10})_{q} \xrightarrow{5} \begin{array}{c} 4 \\ R^{11} \\ T \end{array} \begin{array}{c} 0 \\ S \\ O \end{array} \begin{array}{c} R^{1a} \\ R^{1b} \\ R^{2} \end{array} \begin{array}{c} O \\ R^{3} \\ VII \end{array}$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is: 1, 2, 3, or 4;

T is: O, NR^{1c} or S;

R^{1c} is: hydrogen or C₁-C₆ alkyl;

 R^{10} and R^{11} are each independently:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy,

 C_1 - C_6 alkyl or C_1 - C_6 alkoxy; and

wherein alkyl, aryloxy, and alkoxy being optionally substituted with one or more groups independently selected from R¹⁵.

19. (Original) The compound of Claim 18, wherein the compound having a structural Formula VIII,

$$(R^{10})_{q} \xrightarrow{\begin{array}{c} 5 \\ 6 \end{array}} \xrightarrow{\begin{array}{c} 4 \\ 7 \end{array}} \xrightarrow{\begin{array}{c} 3 \\ 2 \end{array}} \xrightarrow{\begin{array}{c} 11 \\ 13 \end{array}} \xrightarrow{\begin{array}{c} 11 \end{array}} \xrightarrow{\begin{array}{c} 1$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is: 1 or 2;

 R^1 is: C_3 - C_5 alky or $(CH_2)_n$, C_3 - C_6 cycloalkyl;

 R^2 and R^3 are each independently: C_1 - C_3 alkyl;

 R^{10} is: halo, haloalkyl or C_1 - C_3 alkyl, and wherein R^{10} being substituted at a position 5, or 6, or both 5 and 6 of benzothiophenyl

R¹¹ is: hydrogen or C₁-C₆ alkyl.

ring; and

- 20. (Original) The compound of Claim 19, wherein R¹⁰ is Cl, F, Br, CH₃ or CF₃ being substituted at a position 5 of benzothiophenyl ring.
 - 21. (Original) A compound having a structural Formula IX,

$$Z - (CH_2)_m - \begin{matrix} O & & \begin{matrix} R^{1a} & & & \\ I & & & \\ IX \end{matrix}$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

E is: $O, S \text{ or } NR^{14}$;

 $W is: \qquad \qquad R^4 \quad R^5 \ , \ hydrogen, \ C_1\text{-}C_6 \ alkyl, \ (CH_2)_n\text{-}C_3\text{-}C_6 \ cycloalkyl, \ haloalkyl \ or \ acyl;}$

Q is: $-C(O)OR^6$ or R^{6A} ;

X is: a bond, C, O, S or S[O]_p;

Y is: a bond, S, C or O;

Z is: a) aliphatic group,

- b) aryl,
- c) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
- d) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl,
- e) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and
- f) heterocyclyl; wherein aliphatic group, aryl, heteroaryl, bi-aryl, bi-heteroaryl and heterocyclyl being

optionally substituted with one or more groups independently selected from R¹⁵;

m and n' are each independently: 0, 1, 2, 3 or 4;

n is: 0, 1, 2 or 3;

p is: 1 or 2;

r is: 1, 2, 3 or 4;

v is: 1 or 2;

R¹ is: hydrogen,

haloalkyl,

C₁-C₆ alkyl,

 C_1 - C_6 alkyl- C_1 - C_6 alkoxy,

C₁-C₆ alkyl-aryl,

C₂-C₆ alkenyl,

C₂-C₆ alkynyl,

(CH₂)_n·C₃-C₆ cycloalkyl,

 C_1 - C_6 alkoxy,

aryl, or

R¹ and R² together being a 5- to 8-membered heterocyclyl ring, and wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R¹⁵;

R^{1a} and R^{1b} are each independently:

hydrogen,

C₁-C₆ alkyl, or

R¹ and R^{1a}, R¹ and R^{1b}, R² and R^{1a}, R² and R^{1b} or R^{1a} and R^{1b} together being a 3- to 6-membered heterocyclyl or carbocyclyl ring where at least one of R^{1a} and R^{1b} is not hydrogen;

R² is: hydrogen,

haloalkyl,

 C_1 - C_6 alkyl,

 C_1 - C_6 alkyl- C_1 - C_6 alkoxy,

C₁-C₆ alkyl-aryl,

C₂-C₆ alkenyl,

C₂-C₆ alkynyl,

(CH₂)_n,C₃-C₆ cycloalkyl,

C₁-C₆ alkoxy,

aryl, or

R¹ and R² together being a 5- to 8-membered heterocyclyl ring, and wherein alkyl, aryl, alkenyl, alkynyl, cycloalkyl and alkoxy being optionally substituted with one or more groups independently selected from R¹⁵;

 R^{2a} is: hydrogen, halo or C_1 - C_6 alkyl and wherein R^2 and R^{2a} together being a 3- to 8-membered ring; and wherein alkyl being optionally substituted with one or more groups independently selected from R^{15} ;

R³ is: hydrogen, halo, cyano, haloalkyl, C_1 – C_6 alkyl, (CH₂)_n,C₃-C₆ cycloalkyl, (C₁-C₄ alkyl)-heterocyclyl, wherein the heterocyclyl being optionally substituted with oxo, $(C_1-C_4 \text{ alkyl})-NR^7C(O)_pR^9$, and wherein alkyl, cycloalkyl and heterocyclyl being optionally substituted with one or more groups independently selected from R¹⁵; R⁴ and R⁵ are each independently: hydrogen, halo, C₁-C₆ alkyl C_1 - C_6 alkoxy; aryloxy; $N(R^8)_{2}$ SR⁸ or

R⁴ and R⁵ together being a 3- to 8-membered ring: R⁶ is: hydrogen, C₁-C₆ alkyl or aminoalkyl;

R^{6A} is: carboxamide, C₁-C₃ alkylnitrile, sulfonamide, acylsulfonamide or tetrazole;

 R^7 is: hydrogen or C_1 - C_6 alkyl;

R⁸ and R⁹ are each independently:

hydrogen, C₁-C₆ alkyl, aryl, heteroaryl, or heterocyclyl, and wherein aryl, heteroaryl and heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C₁-C₆ alkyl and C₁-C₆ alkoxy;

R¹⁴ is: hydrogen, aryl, C₁-C₆ alkyl, or C₁-C₆ alkyl-COOR⁶, and wherein aryl and alkyl being optionally substituted with one or more groups independently selected from R¹⁵; and

 $R^{15} \text{ is: hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1-C_6 alkyl, C_1-C_6 alkoxy, $(CH_2)_n$-C_3-C_6 cycloalkyl, $N(R^8)_2$, $NR^8S(O)_2R^9$, $NR^8C(O)_pR^9$, $C(O)_NR^8R^9$, $C(O)_pR^8$, SR^8, $S(O)_pR^8$ or $S(O)_2NR^8R^9$.}$

22. (Original) The compound of Claim 21, wherein the compound having a structural Formula X:

$$(R^{10})_q \xrightarrow{\begin{array}{c} 5 \\ 6 \end{array} \end{array} \xrightarrow{\begin{array}{c} 7 \\ 7 \end{array} } \xrightarrow{\begin{array}{c} R^{1a} \\ N \\ 7 \end{array} \xrightarrow{\begin{array}{c} R^{1b} \\ N \end{array} \xrightarrow{\begin{array}{c} R^{1b} \\ R^{1b} \end{array} \xrightarrow{\begin{array}{c} R^{2} \\ X \end{array}} \xrightarrow{\begin{array}{c} R^{2} \\ R^{2} \end{array} \xrightarrow{\begin{array}{c} R^{4} \\ R^{4} \end{array} \xrightarrow{\begin{array}{c} R^{10} \\ R^{10} \end{array} \xrightarrow{\begin{array}{c} 5 \\ 7 \end{array} \xrightarrow{\begin{array}{c} 7 \\ 1 \end{array} \xrightarrow{\begin{array}{\begin{array}{c} 7 \\ 1 \end{array} \xrightarrow{\begin{array}{c} 7 \\ 1 \end{array} \xrightarrow{\begin{array}{c} 7 \end{array} \xrightarrow{\begin{array}{c} 7 \\ 1 \end{array} \xrightarrow{\begin{array}{c} 7 \end{array}$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

n and q are each independently: 1, 2, 3 or 4;

T is: O, NR^{1c} or S;

X is: C, O or S;

R¹ is: hydrogen, C₁-C₆ alkyl or (CH₂)_n·C₃-C₆ cycloalkyl;

R^{1a}, R^{1b}, R^{1c} and R² are each independently: hydrogen or C₁-C₆ alkyl; and

R¹⁰ and R¹¹ are each independently:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, C_1 - C_6 alkyl or C_1 - C_6 alkoxy; and wherein alkyl, alkoxy and aryloxy being optionally substituted with one or more groups selected from R^{15} .

23. (Original) The compound of Claim 22, wherein the compound having a structural Formula XI:

$$(R^{10})_{q} \xrightarrow{5} \xrightarrow{4} \xrightarrow{3} \xrightarrow{0} \underset{S}{\overset{\parallel}{\text{S}}} - \underset{R^{1}}{\overset{\parallel}{\text{N}}} = \underset{R^{2}}{\overset{\parallel}{\text{N}}} = \underset{R}{\overset{\parallel}{\text{N}}} = \underset{R}{\overset{\parallel$$

and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, wherein:

q is 1 or 2;

E is O, S or NR¹⁴;

 R^1 , R^2 and R^{11} are each independently: C_1 - C_4 alkyl;

R¹⁰ is: Cl, F, Br, CH₃ or CF₃, and wherein R¹⁰ being substituted at a position 5, or 6, or both 5 and 6 of benzothiophenyl ring; and

R¹⁴ is: hydrogen, C₁-C₆ alkyl or aryl.

24. (Original) A compound selected from the group consisting of No. 1-120 and 121:

No.	Structure	Name
1	F OH	3-(4-{2-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenyl)-propionic acid
2	CI S S N S	3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenyl)-propionic acid
3	CI S, N O O OH	(4-{2-[(5-Chloro-3-methyl-benzofuran-2-sulfonyl)-propyl-amino]-1-methyl-ethoxy}-2-methyl-phenoxy)-acetic acid

No.	Structure	Name
4	CI OH	(4-{2-[(5-Chloro-3-methyl-benzofuran-2-sulfonyl)-propyl-
		amino]-1-methyl- ethylsulfanyl}-2- methyl-phenoxy)-acetic
		acid
5	CI OH	3-(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenyl)-propionic acid
6	CI OHOH	(4-{2-[(5-Chloro-3-ethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

7	1 1 0	4-{2-[(6-Chloro-3-
		methyl-
	CI	benzo[b]thiophene-2-
	's s s N	sulfonyl)-propyl-
	o´`o	amino]-ethylsulfanyl}-
		2-methyl-phenoxy)-
		acetic acid
8		4-{2-[(7-Chloro-3-
		methyl-
	OH OH	benzo[b]thiophene-2-
		sulfonyl)-propyl-
	0 0	amino]-ethylsulfanyl}-
		2-methyl-phenoxy)-
		acetic acid
9	CI 1 0	(4-{2-[(4-Chloro-3-
		methyl-
	OH	benzo[b]thiophene-2-
	`s s s N	sulfonyl)-propyl-
	0 0	amino]-ethylsulfanyl}-
		2-methyl-phenoxy)-
10	Cl. F	acetic acid
10	~ ~	(4-{2-[(5-Chloro-3-
	F O OH	trifluoromethyl-
		benzo[b]thiophene-2-
	S S, S, N S	sulfonyl)-propyl- amino]-ethylsulfanyl}-
	0 0	2-methyl-phenoxy)-
		acetic acid
11	CI CF ₃ O	(4-{2-[(5-Chloro-3-
		trifluoromethyl-
		benzo[b]thiophene-2-
	S Ö	sulfonyl)-propyl-
		amino]-1-methyl-
		ethoxy}-2-methyl-
		phenoxy)-acetic acid
12	0	2-[4-(3-{[5-(4'-Fluoro-
	I WOXOH	biphenyl-4-yl)-
		thiophene-2-sulfonyl]-
	<u> </u>	propyl-amino}-propyl)-
		phenoxy]-2-methyl-
		propionic acid
13	_ /	2-(4-{2-[(5-Chloro-3-
		methyl-
		benzo[b]thiophene-2-
		sulfonyl)-propyl-
		amino]-ethyl}-
	ci,	phenoxy)-2-methyl-
		propionic acid

14	S O O O O O O O O O O O O O O O O O O O	2-(4-{3-[(3,5-Dimethylbenzo[b]thiophene-2-sulfonyl)-propyl-amino]-propyl}-phenoxy)-2-methyl-propionic acid
15	F O O O O O O O O O O O O O O O O O O O	2-(4-{3-[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-propyl}-phenoxy)-2-methyl-propionic acid
16	CI S N OH	2-(4-{3-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-(2,2,2-trifluoro-ethyl)-amino]-propyl}-phenoxy)-2-methyl-propionic acid
17	S OH	2-(4-{2-[(3-Ethyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethoxy}-3-propyl-phenoxy)-2-methyl-propionic acid
18	CI S-S-O O'S-N O'S-N	2-[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenoxy]-2-methyl-propionic acid
19	CI S OS NO	3-[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenyl]-propionic acid

20	F SOO OS N SOO OS N SOO OS N	[4-(1-{[(5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid
21	CI C	[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid
22	CI S S S S S S S S S S S S S S S S S S S	[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid
23	OH SCH ₃	(2-Methyl-4-{2-[(6-phenoxy-pyridine-3-sulfonyl)-propyl-amino]-ethylsulfanyl} phenoxy)-acetic acid
24	CH ₃ CH ₃ CH ₃ O O O O O O O O O O O O O O O O O O O	(2-Methyl-4-{2-[(5-methyl-1-phenyl-1H-pyrazole-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
25	OH SHOOL CH3	(2-Methyl-4-{2-[(4-oxazol-5-yl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
26	OH SHOO CH ₃ OH	(2-Methyl-4-{2-[propyl-(4-pyrazol-1-yl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid

27	O S CH ₃ OH	(2-Methyl-4-{2-[(2-naphthalen-1-yl-ethanesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
28	F F CH ₃	(2-Methyl-4-{2-[propyl-(4-trifluoromethylphenylmethanesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
29	CH ₃ OH	(4-{2-[(Biphenyl-3-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
30	O CH S CH	(4-{2-[(2,3-Dihydro-benzo[1,4]dioxine-6-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
31	H ₃ C S N S CH ₃ OH	[2-Methyl-4-(2-{[5-(2-methylsulfanyl-pyrimidin-4-yl)-thiophene-2-sulfonyl]-propyl-amino}-ethylsulfanyl)-phenoxy]-acetic acid
32	F H ₃ C CH ₃	[2-Methyl-4-(2-{[5-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-sulfonyl]-propyl-amino}-ethylsulfanyl)-phenoxy]-acetic acid
33	F F S O CH ₃ O O O O O O O O O O O O O O O O O O O	[2-Methyl-4-(2-{[5-(1-methyl-3-trifluoromethyl-1H-pyrazol-4-yl)-thiophene-2-sulfonyl]-propyl-amino}-ethylsulfanyl)-phenoxy]-acetic acid
34	F CH ₃ chiral S CH ₃ CH ₃ OH	(R)-(2-Methyl-4-{1- methyl-2-[(3-methyl-5- trifluoromethyl- benzo[b]thiophene-2- sulfonyl)-propyl-

		ominal attention(form)
		amino]-ethylsulfanyl}- phenoxy)-acetic acid
35	ÇH₃ chiral	(R)-3-(4-{2-[(6-Chloro-
		5-fluoro-3-methyl-
		benzo[b]thiophene-2-
	CI S O CH3	sulfonyl)-propyl-
		amino]-1-methyl-
	сн₃ о́н	ethylsulfanyl}-2-
		methyl-phenyl)-
		propionic acid
36	ÇH₃ chiral	(R)-(4-{2-[(6-Chloro-5-
	F CH ₃	fluoro-3-methyl-
		benzo[b]thiophene-2-
		sulfonyl)-propyl-
	The character of the ch	amino]-1-methyl-
	ĊH₃ ŎĦ	ethylsulfanyl}-2-
		methyl-phenoxy)-acetic
		acid
37	0	(4-{2-[(4-Bromo-
	O II S CH ₃	benzenesulfonyl)-
		propyl-amino]-
	Br. O	ethylsulfanyl}-2-
		methyl-phenoxy)-acetic
	ĊH ₃ ÖH	acid
38		(4-{2-[(3,4-Dichloro-
	CI S CH ₃	benzenesulfonyl)-
		propyl-amino]-
		ethylsulfanyl}-2-
		methyl-phenoxy)-acetic
	3	acid
39	0	(4-{2-[(4-Isopropyl-
	S CH ₃	benzenesulfonyl)-
	H ₃ C	propyl-amino]-
		ethylsulfanyl}-2-
	H CH3 CH3 OH	methyl-phenoxy)-acetic
		acid
40	O II S CH ₃	(2-Methyl-4-{2-[(4-
	S N CH3	pentyl-
		benzenesulfonyl)-
	H³c, A A A A A A A A A A A A A A A A A A A	propyl-amino]-
	CH ₃ OH	ethylsulfanyl}-
		phenoxy)-acetic acid
41	CI O	(4-{2-[(2-Chloro-4-
	S CH ₃	trifluoromethyl-
		benzenesulfonyl)-
		propyl-amino]-
		ethylsulfanyl}-2-
		methyl-phenoxy)-acetic
		acid

42	F F O S N S CH ₃	(2-Methyl-4-{2-[propyl- (3-trifluoromethyl- benzenesulfonyl)- amino]-ethylsulfanyl}- phenoxy)-acetic acid
43	CH ₃ O CH ₃ CH ₃ O O O O O O O O O O O O O O O O O O O	(4-{2-[(4-Bromo-2-methyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
44	Br CH ₃ CH ₃ OH	(4-{2-[(3,4-Dibromobenzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
45	H ₃ C CH ₃ CH ₃ OH	(2-Methyl-4-{2-[propyl- (4-propyl- benzenesulfonyl)- amino]-ethylsulfanyl}- phenoxy)-acetic acid
46	CI ON S N S CH ₃ OH	(4-{2-[(2,4-Dichlorobenzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
47	CH ₃ CH ₃ OH	(4-{2-[(4-Iodo-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

48	O II CH ₃	(4-{2-[(3-Chloro-4- methyl-
		benzenesulfonyl)-
	H ₃ C O	propyl-amino]- ethylsulfanyl}-2-
	ĊH₃ ÖH	methyl-phenoxy)-acetic
		acid
49	F O I	(4-{2-[(4-Bromo-2,5-difluoro-
	S N CH3	benzenesulfonyl)-
	Br	propyl-amino]-
	I I I I OH	ethylsulfanyl}-2-
	•	methyl-phenoxy)-acetic acid
50	o chiral	(2-Methyl-4-{1-methyl-
		2-[propyl-(4- trifluoromethyl-
	F CH ₃	benzenesulfonyl)-
	F CH ₃ OH	amino]-ethylsulfanyl}- phenoxy)-acetic acid
51	chiral	(4-{2-[(3,4-Dichloro-
		benzenesulfonyl)-
	CH ₃	propyl-amino]-1- methyl-ethylsulfanyl}-
	CI CH ₃	2-methyl-phenoxy)-
	Ċн _з ÓН	acetic acid
52	O	(2-Methyl-4-{2-[propyl- (2'-trifluoromethyl-
	F Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	biphenyl-4-sulfonyl)-
		amino]-ethylsulfanyl}-
	ĊH ₃ OH	phenoxy)-acetic acid
53	O III	(2-Methyl-4-{2-[propyl-(3'-trifluoromethyl-
		biphenyl-4-sulfonyl)-
	F CH ₃ OH	amino]-ethylsulfanyl}-
54	, oli	phenoxy)-acetic acid (2-Methyl-4-{2-[propyl-
	S N S CH3	(4'-trifluoromethyl-
		biphenyl-4-sulfonyl)-
	F CH ₃ OH	amino]-ethylsulfanyl}- phenoxy)-acetic acid
	F	
55	O CH ₃	(4-{2-[(2'-Fluoro-biphenyl-4-sulfonyl)-
		propyl-amino]-
		ethylsulfanyl}-2-
	ĊН ₃ ОН	methyl-phenoxy)-acetic acid
		acia

56	O O O CH ₃	(4-{2-[(4'-Fluoro-biphenyl-4-sulfonyl)-
	CH ₃ OH	propyl-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid
57	F F O OH	(2-Methyl-4-{2-[propyl- (4'-trifluoromethoxy- biphenyl-4-sulfonyl)- amino]-ethylsulfanyl}- phenoxy)-acetic acid
58	CI CH ₃ CH ₃	(4-{2-[(3',4'-Dichlorobiphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-aceticacid
59	F CH ₃ CH ₃ OH	(4-{2-[(3'-Fluoro-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
60	CI CH ₃ CH ₃ OH	(4-{2-[(2'-Chloro-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
61	CI CH ₃ CH ₃ OH	(4-{2-[(4'-Methoxy-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
62	H ₃ C _O OH	(4-{2-[(4'-Methoxy-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
63	CI CH ₃ OH	(4-{2-[(3'-Chloro-4'-fluoro-biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

64	F F O S N S CH ₃ CH ₃ O O O O O O O O	(4-{2-[(4-Chloro-3-trifluoromethyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
65	Chiral CH ₃ CH ₃ CH ₃ OH	(2-Methyl-4-{1-methyl-2-[propyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
66	H ₃ C CH ₃ CH ₃ OH	(2-Methyl-4-{1-methyl-2-[propyl-(4-propyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
67	CH ₃ Chiral CH ₃ CH ₃ CH ₃ OH	(4-{2-[(4-Chloro-3-trifluoromethyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
68	CI CH ₃ CH ₃ CH ₃ OH	(4-{2-[(3-Chloro-4-trifluoromethyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
69	H ₃ C CH ₃ OH	(4-{2-[(4-Butyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-aceticacid
70	H ₃ C CH ₃ CH ₃ OH	(4-{2-[(4-Isobutyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-aceticacid
71	CI O chiral CH ₃ CH ₃ CH ₃ OH	(4-{2-[(2-Chloro-4-trifluoromethyl-benzenesulfonyl)-propyl-amino]-1-methyl-ethylsulfanyl}-

		2 41: 11:)
		2-methyl-phenoxy)-
72	0 .1:1	acetic acid
72	O chiral	(4-{2-[(4-Bromo-3-
		chloro-
	CH ₃	benzenesulfonyl)-
	Br O I I 3	propyl-amino]-1-
	ch₃ oh	methyl-ethylsulfanyl}-
	- 3	2-methyl-phenoxy)-
	11.1	acetic acid
73	O chiral	(4-{2-[(4-Butyl-3-
		chloro-
	H ₃ C CH ₃ CH ₃	benzenesulfonyl)-
		propyl-amino]-1-
	ĊH₃ ÖH	methyl-ethylsulfanyl}-
		2-methyl-phenoxy)-
		acetic acid
74	O chiral	(4-{2-[(3-Chloro-4-
		isobutyl-
		benzenesulfonyl)-
	H ₃ C V V	propyl-amino]-1-
	CH ₃ OH	methyl-ethylsulfanyl}-
		2-methyl-phenoxy)-
		acetic acid
75	O chiral	(4-{2-[(4-Bromo-
	S CH ₃	benzenesulfonyl)-
	CH ₃	propyl-amino]-1-
	Br CH ₃	methyl-ethylsulfanyl}-
	CH ₃ OH	2-methyl-phenoxy)-
	3	acetic acid
76	O chiral	(4-{2-[(4-Butyl-
		benzenesulfonyl)-
	H ₃ C CH ₃ CH ₃	propyl-amino]-1-
		methyl-ethylsulfanyl}-
	ĊН ₃ ОН	2-methyl-phenoxy)-
	1 • 1	acetic acid
77	chiral	(4-{2-[(2-Chloro-4'-
		fluoro-biphenyl-4-
	CH ₃	sulfonyl)-propyl-
		amino]-1-methyl-
	cH₃ ÓH	ethylsulfanyl}-2-
		methyl-phenoxy)-acetic
70	C chiral	acid
78	٥. ١١	(4-{2-[(3-Chloro-4-
		propyl-
	CH ₃	benzenesulfonyl)-
		propyl-amino]-1-
	ĊH ₃ ÖH	methyl-ethylsulfanyl}-
		2-methyl-phenoxy)-
		acetic acid

79	CH₃	(4-{2-[(5-Chloro-3-
	CI CH ₃ O S OH	methyl-
	CI S OH	benzo[b]thiophene-2-
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	sulfonyl)-propyl-
	✓ 'S 0 \	amino]-ethylsulfanyl}-
	ĊH₃	2-propyl-phenoxy)-
00	OI I	acetic acid
80	CI CH ₃ O OH	(4-{2-[(5-Chloro-3-
	I I S O S OH	methyl-
	S N C	benzo[b]thiophene-2-
	<u> </u>	sulfonyl)-propyl-
	Ċн _з	amino]-ethylsulfanyl}-
81	F	phenoxy)-acetic acid (4-{2-[(5-Chloro-3-
01		methyl-
	CH S	benzo[b]thiophene-2-
	CI S O O	sulfonyl)-propyl-
	S OH	amino]-ethylsulfanyl}-
	* ° ° /	2-trifluoromethyl-
	CH ₃	phenoxy)-acetic acid
82	F,F,F	[2-Methyl-4-(1-
	'Υ' ÇH₃ ÇH₃ Ω	{[propyl-(4-
	OCH OH	trifluoromethoxy-
		benzenesulfonyl)-
		amino]-methyl}-
	0 0	propylsulfanyl)-
		phenoxy]-acetic acid
83	CH ₃	(4-{2-[(5-Chloro-3-
	CH ₃ S—O O	methyl-
		benzo[b]thiophene-2-
	Ç N CH₃ OH	sulfonyl)-propyl-
	~ \$ 0 }	amino]-1-methyl-
	CH ₃	ethylsulfanyl}-2-
	Š	methyl-phenoxy)-acetic
84	,CH ₃	acid (4.12.1(5.Chloro.3
04		(4-{2-[(5-Chloro-3-methyl-
	CH ₃ O S O O	benzo[b]thiophene-2-
		sulfonyl)-propyl-
	S CH ₃ OH	amino]-1-methyl-
	, , ,	ethylsulfanyl}-2-
	CH ₃	methyl-phenoxy)-acetic
	·	acid
85	F, CH ₃ CH ₃	(2-Methyl-4-{2-[(3-
	F CH ₃ CH ₃	methyl-5-
	ˈ 【 【 》 —ÿ-N CH₃	trifluoromethyl-
	s ö 🥄	benzo[b]thiophene-2-
	s= <u>(</u>)o	sulfonyl)-propyl-
	ОН	amino]-ethylsulfanyl}-
		phenoxy)-acetic acid

86	F CH ₃ CH ₃ CH ₃ CH ₃ OH	(2-Methyl-4-{2-[propyl-(4-trifluoromethyl-benzenesulfonyl)-amino]-ethylsulfanyl}-phenoxy)-acetic acid
87	CH ₃ O CH ₃ O O O O O O O O O O O O O O O O O O O	(4-{2-[(4-Ethyl-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
88	OH OH OH OH OH OH OH OH OH OH	(2-Methyl-4-{2-[(2-methyl-4-trifluoromethoxy-benzenesulfonyl)-propyl-amino]-ethylsulfanyl}-phenoxy)-acetic acid
89	FF F O O O O O O O O O O O O O O O O O	(2-Methyl-4-{2-[propyl- (4-trifluoromethoxy- benzenesulfonyl)- amino]-ethylsulfanyl}- phenoxy)-acetic acid
90	CH ₃ OH OH	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
91	CH ₃ O O O O O O O O O O O O O O O O O O O	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-(3-methyl-butyl)-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid

92	CH ₃ O _S S-NOOH	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-cyclopropyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
93	CH ₃ O _S O _S O _O O _O O	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-cyclobutyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
94	CH ₃ OH OH	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-cyclopropylmethyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
95	CH ₃ O O O O O O O O O O O O O O O O O O O	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-pentyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
96	CH ₃ CH ₃ OH OH	(4-{2-[Butyl-(5-chloro- 3-methyl- benzo[b]thiophene-2- sulfonyl)-amino]- ethylsulfanyl}-2- methyl-phenoxy)-acetic acid
97	CH ₃ CH ₃ CH ₃ OH	(4-{2-[(Biphenyl-4-sulfonyl)-propyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
98	CI CH ₃ O O O O O O O O O O O O O O O O O O O	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-ethoxy}-2-methyl-phenylsulfanyl)-

		acetic acid
99	,CH₃	(4-{3-[(5-Chloro-3-
		methyl-
	CI S S O O O O O O O O O O O O O O O O O	benzo[b]thiophene-2-
	S-N OH	sulfonyl)-propyl-
	s' i '\	amino]-propyl}-2-
	\ \ \	
	CH ₃	methyl-phenoxy)-acetic acid
100	,CH ₃	
100		(4-{2-[(5-Chloro-3-
	CI CH ₃ O CH ₃ OH	methyl-
		benzo[b]thiophene-2-
	│	sulfonyl)-propyl-
		amino]-1-methyl-
	CH ₃	ethoxy}-2-methyl-
101		phenoxy)-acetic acid
101	CH₃	3-(4-{2-[(5-Chloro-3-
	CH₃ O—⟨¯⟩ O	methyl-
		benzo[b]thiophene-2-
	[´ N−ÿ−n(CH₃ OH	sulfonyl)-propyl-
	✓ s ö ⟩	amino]-1-methyl-
	CH ₃	ethoxy}-2-methyl-
100	-	phenyl)-propionic acid
102	CH ₃	2-(4-{2-[(5-Chloro-3-
	СН ₃ О— О О	methyl-
	CI CH ₃ H ₃ C OH	benzo[b]thiophene-2-
	CI CH ₃ H ₃ C OH	sulfonyl)-propyl-
	s ö	amino]-1-methyl-
	\ 	ethoxy}-2-methyl-
	CH ₃	phenoxy)-2-methyl-
102	0.011	propionic acid
103	O-CH ₃	3-(4-{2-[(5-Chloro-3-
	l çh₃ o—⟨¯⟩— o	methyl-
	CI CH ₃ O CH ₂ OH	benzo[b]thiophene-2-
	S-N CH3 OH	sulfonyl)-propyl-
	~ 3 0 /	amino]-1-methyl-
	CH ₃	ethoxy}-2-methoxy-
104	, CH ₃	phenyl)-propionic acid
104	, · · · · · · · · · · · · · · · · · · ·	(4-{2-[(5-Fluoro-3-methyl-
		1 *
	F CH ₃ S O O O O O O O O O O O O O O O O O O	benzo[b]thiophene-2-sulfonyl)-propyl-
		amino]-1-methyl-
	• • • (ethylsulfanyl}-2-
	CH ₃	methyl-phenoxy)-acetic
	Ĭ	acid
		aciu

105	CH₃	3-(4-{2-[(5-Fluoro-3-
	F CH ₃ O CH ₃ OH	methyl- benzo[b]thiophene-2-
	Г Г № ", СН3 ОН	sulfonyl)-propyl-
	(amino]-1-methyl- ethoxy}-2-methyl-
	, СН³	phenyl)-propionic acid
106	CH ₃	(4-{2-[(5-Fluoro-3-
		methyl- benzo[b]thiophene-2-
	F S O CH ₃ OH	sulfonyl)-propyl-
	s ö	amino]-1-methyl-
	, CH³	ethoxy}-2-methyl- phenoxy)-acetic acid
107	,CI	(2-Chloro-4-{2-[(5-
	сн₃ ѕ— о о	chloro-3-methyl- benzo[b]thiophene-2-
	CI OH OH	sulfonyl)-propyl-
	s' ö'	amino]-ethylsulfanyl}-
	CH ₃	phenoxy)-acetic acid
108	ÇH ₃ CH ₂	(4-{2-[(5-Chloro-3-
	CI CH ₃	methyl-
	✓ `s ö └┐ ──	benzo[b]thiophene-2- sulfonyl)-propyl-
	s————	amino]-ethylsulfanyl}-
	ОН	2-ethyl-phenoxy)-acetic acid
109	OH	(2-Methyl-4-{2-
	O= CH ₃	[(naphthalene-2-
	CH ₃	sulfonyl)-propyl- amino]-ethylsulfanyl}-
		phenoxy)-acetic acid
	o's'	
	0,5	
110		(4-{2-[(5-Fluoro-3-
	H ₃ C O	methyl- benzo[b]thiophene-2-
	N-S T CH ₃	sulfonyl)-propyl-
	H ₃ C	amino]-ethylsulfanyl}-
	HO	2-methyl-phenoxy)- acetic acid
	őő	

111	F. CH ₃ CH ₃	[3-Chloro-4-(1- {[propyl-(4-
	$ \begin{array}{c c} F & O & S & O \\ F & O & S & O \\ F & O & O & O \end{array} $	trifluoromethoxy- benzenesulfonyl)- amino]-methyl}-
		propylsulfanyl)-phenyl]- acetic acid
112	CI S S O Chiral	(R)-(3-Chloro-4-{2-[(5-chloro-3-methyl-
	CI SHN CH _Q CI OH	benzo[b]thiophene-2- sulfonyl)-propyl-
	CH ₃	amino]-1-methyl- ethylsulfanyl}-phenyl)-
112		acetic acid
113	CH, S	(3-Chloro-4-{2-[(5-chloro-3-methyl-
	S O HO	benzo[b]thiophene-2-sulfonyl)-propyl-
	CH ₃	amino]-ethylsulfanyl}- phenyl)-acetic acid
114	ÇH ₃ O	[4-(1-{[(5-Fluoro-3-methyl-
	L CH₃ L C L C L C L C L C L C L C L C L C L	benzo[b]thiophene-2- sulfonyl)-propyl-
	S N OH	amino]-methyl}- propoxy)-2-methyl-
	CH ³ C	phenoxy]-acetic acid
115	F ÇH₃ O	3-[4-(1-{[(5-Fluoro-3-methyl-
	I V ∕ CH₃	benzo[b]thiophene-2- sulfonyl)-propyl-
	SINO	amino]-methyl}-
	H ₃ C CH ₃ C	propoxy)-2-methyl- phenyl]-propionic acid
116	CI\	3-(4-{2-[(5-Chloro-3- methyl-
	CH ₃ CH ₃ OH	benzo[b]thiophene-2-
	s is in	sulfonyl)-propyl- amino]-butoxy}-2-
		methyl-phenyl)- propionic acid
	CH ₃	

117	CI CH ₃ OH OH CH ₃ CH ₃ CH ₃	[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methyl-phenoxy]-acetic acid
118	CH ₃ O CH ₃	[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propoxy)-2-methoxy-phenoxy]-acetic acid
119	CH ³ O O O O O O O O O O O O O O O O O O O	(4-{2-[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-phenethyl-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
120	CH ₃ OHOH	(4-{2-[Benzyl-(5-chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-amino]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid
121	CH ₃ O OH S OH S CH ₃ CH ₃	[4-(1-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonyl)-propyl-amino]-methyl}-propylsulfanyl)-2-methyl-phenoxy]-aceticacid

25. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound of Claim 1 or pharmaceutically acceptable salts, solvates or hydrates thereof.

- 26. (Cancelled)
- 27. (Cancelled)

- 28. (Cancelled)
- 29. (Cancelled)
- 30. (Cancelled)
- 31. (Cancelled)
- 32. (Cancelled)
- 33. (Cancelled)
- 34. (Previously Presented) A method for lowering blood-glucose in a mammal comprising the step of administering an effective amount of at least one compound of Claim 1.
 - 35. (Cancelled)
 - 36. (Cancelled)
 - 37. (Cancelled)
 - 38. (Cancelled)
 - 39. (Cancelled)
 - 40. (Cancelled)